343781-41-9

Basic information

• Product Name: 3,5-DICHLORO-4-IODOPYRIDINE, 97%
• Synonyms: 3,5-Dichloro-4-iodopyridine;ZINC02243486
• CAS NO: 343781-41-9
• Molecular Formula: C₅H₂Cl₂IN
• Molecular Weight: 273.89
• Product Categories: C5Heterocyclic Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyridines
• Mol File: 343781-41-9.mol
• Article Data: 4

Chemical Properties

• Melting Point: 186-190 °C(lit.)
• Boiling Point: 271.6 °C at 760 mmHg
• Flash Point: 118.1 °C
• Appearance: /
• Density: 2.129 g/cm³
• Vapor Pressure: 0.0106mmHg at 25°C
• Refractive Index: 1.652
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3,5-DICHLORO-4-IODOPYRIDINE, 97%(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DICHLORO-4-IODOPYRIDINE, 97%(343781-41-9)
• EPA Substance Registry System: 3,5-DICHLORO-4-IODOPYRIDINE, 97%(343781-41-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22-37/38-41
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 343781-41-9(Hazardous Substances Data)

Usage

General Description

3,5-Dichloro-4-iodopyridine, 97% is a chemical compound with the molecular formula C5H2Cl2IN. It is a heterocyclic organic compound that is predominantly used in the pharmaceutical and agrochemical industries as a key building block in the synthesis of various pharmaceutical drugs and crop protection chemicals. 3,5-DICHLORO-4-IODOPYRIDINE, 97% is also utilized as a reagent in organic synthesis, specifically in the preparation of biologically active compounds. Its high purity of 97% suggests that it is a highly reliable and effective chemical for use in research and production processes.

InChI:InChI=1/C5H2Cl2IN/c6-3-1-9-2-4(7)5(3)8/h1-2H

Upstream product

• 2457-47-8 3,5-dichloropyridine 
• 200711-45-1 3,4,5-trichloro-pyridine-2-carboxylic acid methyl ester 
• 846045-08-7 3,5-dichloro-4-hydroxy-pyridine-2-carboxylic acid 
• 5439-04-3 3,4,5-trichloropicolinic acid 

Downstream Products

• 1401468-87-8 (S)-benzyl 2-(tert-butoxycarbonylamino)-5-(3,5-dichloropyridin-4-yl)pent-4-ynoate 
• 1370286-80-8 N'-(3,5-dichloropyridin-4-yl)-N-methyl-3-phenylpropanehydrazide 
• 1370287-74-3 3,5-dichloro-4-(2-(3-phenylpropyl)hydrazin-1-yl)pyridine 
• 688309-95-7 N'-(3,5-dichloro-pyridine-4-yl)-3-phenylpropanehydrazide 
• 1370287-10-7 4-cyclohexyl-N'-(3,5-dichloropyridin-4-yl)butanehydrazide 
• 1370287-09-4 2-cyclohexyl-N'-(3,5-dichloropyridin-4-yl)acetohydrazide 
• 1370287-07-2 3-cyclohexyl-N'-(3,5-dichloropyridin-4-yl)propanehydrazide 
• 1370286-98-8 (E)-N'-(3,5-dichloropyridin-4-yl)cinnamoylhydrazide 
• 1370286-97-7 N-benzyl-2-(3,5-dichloropyridin-4-yl)hydrazinecarboxamide 
• 1370286-96-6 benzyl 2-(3,5-dichloropyridin-4-yl)hydrazinecarboxylate 
• 1370286-95-5 N'-(3,5-dichloropyridin-4-yl)-7-phenylheptanehydrazide 
• 1370286-94-4 N'-(3,5-dichloropyridin-4-yl)-6-phenylhexanehydrazide 
• 1370286-93-3 N'-(3,5-dichloropyridin-4-yl)-5-phenylpentanehydrazide 
• 1370286-78-4 N'-(3,5-dichloropyridin-4-yl)-4-phenylbutanehydrazide 

Relevant articles and documents

PYRAZOLE AMIDE DERIVATIVE

The present invention relates to a novel compound having a function of inhibiting RORγ activity. The present invention also relates to pharmaceutical composition comprising the compound, a use of the compound in treating or preventing autoimmune diseases, inflammatory diseases, metabolic diseases, or cancer diseases.

Deprotonation of chloropyridines using lithium magnesates

Chloropyridines are deprotonated using lithium magnesates. 4-Chloropyridine was deprotonated on treatment with 1/3 equiv of the highly coordinated magnesate Bu3(TMP)MgLi2 in THF at -10°C, as evidenced by trapping with I2. The use of Bu(TMP)2MgLi in Et 2O allowed the reaction of 2-chloropyridine, giving the 3-functionalized derivative as the main product. Mixtures of 3- and 4-functionalized derivatives were obtained when 2,6-dichloropyridine was involved in the reaction. Performing the reaction on 3-chloropyridine with lithium magnesates in THF, either the 4,4′-dimer or the 4-iodo derivative was formed after quenching by I2, the former using 1/3 equiv of Bu2(TMP)MgLi and the latter using 1 equiv of (TMP)3MgLi. Similar results were observed with 3,5-dichloropyridine, 2,5-dichloropyridine and 3-chloro-2-fluoropyridine. 1,2-Migration of the lithium arylmagnesate formed by deprotonation was proposed to justify the dimers formation.